This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Mitsui Chemicals


Mitsui Chemicals launched its VISION 2030 Long-Term Business Plan in June 2021, aiming to establish solutions-based business models that resolve social challenges. Positioning Life & Healthcare Solutions as the first pillar in the company’s growth strategy, Mitsui Chemicals aims to provide solutions that contribute to life, health and comfortable lifestyles by creating new products and technologies based on fine chemicals technologies.

Mitsui Chemicals invested in NATiAS Inc. a startup with liquid-phase synthesis technology for high-quality oligonucleotide active pharmaceutical ingredients (APIs) and agreed a business alliance with them in 2022. Mitsui Chemicals and our partner NATiAS are developing a business as an oligonucleotide therapeutics contract development and manufacturing organization (CDMO) capable of providing everything from raw materials and intermediates to APIs. Stakeholders will be delivered solutions through NATiAS’s liquid-phase synthesis technology, its own oligonucleotide intermediates Blockmer™ and Mitsui Chemicals’ own strengths in enzyme and precision organic synthesis technologies.